Quality of thawed hematopoietic progenitor cell grafts
Abstract
Background:
The appropriate dose of compatible and viable hematopoietic progenitor cells (HPC) is crucial for successful engraftment of transplanted cells within patients. In the study we therefore checked the viability of HPC in thawed HPC grafts which were transplanted into haematology patients in one year.
Methods:
We acquired HPC by apheresis and froze them in a programmable freezer in autologous plasma with 10 % DMSO and stored them in liquid nitrogen vapour. We thawed the bags with HPC in a water bath at the patient's bedside and in the eluate residues from the bags after the addition of saline solution we determined the viability (7-AAD) of HPC (CD34 +) and lymphocytes by flow cytometry.
Results:
After the transplantation of HPC, the viability of HPC was 79.9 ± 12.4 % and of leukocytes 62.2 ± 12.2 % (paired t-test, P < 0.001) in cell suspension residues (n = 88). The average viability of HPC in samples which were frozen immediately after collection (n = 58) was 79.9 ± 9.2 % and in samples frozen the next day after 18 hours in the fridge, the viability was 80.5 ± 11.3 % (n = 67). Storing samples overnight did not significantly affect the viability of cells in comparison with samples which were frozen immediately (t-test, P > 0.5). Rinsing of HPC bags and storing cells after thawing in saline solution significantly (n = 7; paired t-test, P <0.01) increased the mortality of HPC, since the viability immediately after thawing was 84.1 ± 4.5 % and in samples diluted with saline solution 60.1 ± 15.7 %.
Conclusions:
In our laboratory, cca 20 % of HPC are lost during freezing and thawing of HPC grafts. Freezing HPC grafts 18 hours after cell collection does not affect the viability of thawed cells in comparison with grafts which are frozen immediately. Saline solution is not suitable for rinsing bags and storing HPC residuals after thawing HPC products.
Downloads
References
Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW. Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. Cytometry B Clin Cytom. 2009;76:18–26.
Aroviita P, Teramo K, Hiilesmaa V, Kekomäki R. Cord blood hematopoietic progenitor cell concentration and infant sex. Transfusion 2005; 45:613–21.
Krašna M, Telebak T, Domanović D. Analysis of cord blood units donated to the Slovenian cord blood bank. Zdrav Vestn 2009;78:451–455.
Keeney M, Gratama JW, Sutherland DR. Critical role of flow cytometry in evaluating peripheral blood hematopoietic stem cell grafts. Cytometry A. 2004; 58:72–5.
Demirer T, Buckner CD, Bensinger WI.. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14:106–16.
Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437–4445.
Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al.. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617–24.
Slovenija-transplant. Mesečna statistika presaditve krvotvornih matičnih celic (KMC) 2013. Dosegljivo 1.9.2014 s spletne strani: http://www.slovenija-transplant.si/fileadmin/SlikovniMaterial/Dejavnost/KMC_December_2013.pdf.
Zver S. Smernice za odkrivanje in zdravljenje kronične limfatične levkemije. Zdrav Vestn 2010; 79: 465–74.
Jazbec J, Rajić V, Karas-Kuželički N. Levkemije otroške dobe. Zdrav Vestn 2008; 77: I-25–30.
Zver A, Zver S, Mlakar U, Preložnik-Zupan I, Pretnar J. Zdravljenje bolnikov z diseminiranim plazmocitomom s tandemsko avtologno presaditvijo krvotvornih matičnih celic v Sloveniji. Zdrav Vestn 2008; 77: I-75–80.
Rosskopf K, Ragg SJ, Worel N, Grommé M, Preijers FW, Braakman E, et al. Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow). Vox Sang 2011; 101:255–75.
McGregor M, Baier D, Duffy M, Graf A, Hutchins C, Philippe J, et al. WMDA Guidance on setting a temperature specification for the transit of HSC donations. World Marrow Donor Association 2010. Dosegljivo 1.9.2014 s spletne strani: http://worldmarrow.org/fileadmin/Committees/QAWG/20101104-QAWG-INFO-HPC_Transit_specification.pdf
Yang H, Acker JP, Cabuhat M, McGann LE. Effects of incubation temperature and time after thawing on viability assessment of peripheral hematopoietic progenitor cells cryopreserved for transplantation. Bone Marrow Transplant. 2003; 32:1021–6.
Halle P, Tournilhac O, Knopinska-Posluszny W, Kanold J, Gembara P, Boiret N, et al. Uncontrolled-rate freezing and storage at -80 degrees C, with only 3.5-percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations. Transfusion 2001; 41:667-73.
Winter JM, Jacobson P, Bullough B, Christensen AP, Boyer M, Reems JA. Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. Cytotherapy 2014; 16:965-75.
Laroche V, McKenna DH, Moroff G, Schierman T, Kadidlo D, McCullough J. Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples. Transfusion. 2005; 45:1909-16.
Yang H, Acker JP, Cabuhat M, Letcher B, Larratt L, McGann LE. Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment. Bone Marrow Transplant. 2005; 35:881-7.
Yang H, Zhao H, Acker JP, Liu JZ, Akabutu J, McGann LE. Effect of dimethyl sulfoxide on post-thaw viability assessment of CD45+ and CD34+ cells of umbilical cord blood and mobilized peripheral blood. Cryobiology 2005; 51:165-75.
D'Rozario J, Parisotto R, Stapleton J, Gidley A, Owen D. Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation. Transfus Apher Sci. 2014; 50:443-50.
Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002; 29:967-72.
Castelhano MV, Reis-Alves SC, Vigorito AC, Rocha FF, Pereira-Cunha FG, De Souza CA, Lorand-Metze I. Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfus Apher Sci. 2013 Apr;48(2):241-6.
Scerpa MC, Daniele N, Landi F, Caniglia M, Cometa AM, Ciammetti C, Rossi C, Locatelli F, Isacchi G, Zinno F. Automated washing of human progenitor cells: evaluation of apoptosis and cell necrosis. Transfus Med. 2011; 21:402-7.
De Boer F, Dräger AM, Pinedo HM, Kessler FL, van der Wall E, Jonkhoff AR, et al. Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 2002; 29:249-55.
Schuurhuis GJ, Muijen MM, Oberink JW, de Boer F, Ossenkoppele GJ, Broxterman HJ. Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants. Bone Marrow Transplant. 2001; 27:487-98.
Parkins MD, Bahlis N, Brown C, Savoie L, Chaudhry A, Russell JA, et al. Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation. Bone Marrow Transplant. 2006; 38:609-14.
Schaefer UW, Schmidt CG, Dicke KA, van Bekkum DW, Schmitt G. Cryopreservation of hemopoietic stem cells. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975; 83:285-91.
Song YS, Moon S, Hulli L, Hasan SK, Kayaalp E, Demirci U. Microfluidics for cryopreservation. Lab Chip 2009;9:1874-81.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
